Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 · Pfizer · PHASE3 · terminated · last registry update 2019-01-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety issues were identified.” | – | Registry record, Pfizer |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD22 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-08-02Results posted on the registry: Pfizer, inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone + inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone (NCT01055496)
- 2019-05-22Phase 3 first posted: Children's Oncology Group, Blinatumomab + Calaspargase Pegol (NCT03959085)
- 2019-05-22Results posted on the registry: M.D. Anderson Cancer Center, CMC-544 (Inotuzumab Ozogamycin) + Rituximab (NCT01134575)
- 2019-03-15Results posted on the registry: Pfizer, Inotuzumab Ozogamicin (CMC-544) + Rituximab (Rituxan) (NCT00724971)
- 2018-10-26Results posted on the registry: Pfizer, Inotuzumab ozogamicin [CMC-544] (NCT00073749)
- 2018-10-03Results posted on the registry: UCB Pharma, Epratuzumab + Epratuzumab (NCT01408576)
- 2018-08-14Phase 3 first posted: Novartis Pharmaceuticals, Tisagenlecleucel + Blinatumomab (NCT03628053)
- 2018-06-29Results posted on the registry: UCB Pharma, Placebo + Epratuzumab (NCT01261793)
- 2018-06-29Results posted on the registry: UCB Pharma, Epratuzumab + Epratuzumab (NCT01262365)
- 2018-04-19Results posted on the registry: Genentech, Inc., Obinutuzumab + Pinatuzumab Vedotin (NCT01691898)
- 2018-03-08Results posted on the registry: Pfizer, inotuzumab ozogamicin + inotuzumab ozogamicin (NCT00299494)
- 2018-02-22Also stopped (terminated): Weill Medical College of Cornell University, 90Y-epratuzumab tetraxetan + veltuzumab (NCT01147393)
- 2018-01-17Results posted on the registry: Pfizer, inotuzumab ozogamicin + FLAG (fludarabine, cytarabine and G-CSF) (NCT01564784)
- 2018-01-09Results posted on the registry: Pfizer, inotuzumab ozogamicin + rituximab (NCT00562965)
- 2018-01-09Also stopped (terminated): Pfizer, inotuzumab ozogamicin + rituximab (NCT00562965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision